Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This consensus statement provides expert guidance on prescribing low-dose oral minoxidil for hair loss, noting a lack of representation of pediatric specialists and highlighting areas for future research.

This study found that oral JAK inhibitors, ruxolitinib and tofacitinib, are effective and well-tolerated for treating severe alopecia areata, with a similar degree of hair regrowth and relapse rates, but ruxolitinib induced faster initial hair regrowth.

This study reports that a 9-week-old infant with Netherton syndrome showed rapid and sustained symptom improvement, including skin microbiome normalization and developmental progress, after off-label dupilumab treatment, without adverse reactions.

In this study, low-dose naltrexone significantly reduced erythema in patients with frontal fibrosing alopecia and lichen planopilaris after one year, but no significant improvements were seen in other symptoms.

This report describes a rare case of painless thyroiditis induced by prolonged off-label use of Lugol’s solution in a 59-year-old woman.

This article discusses challenges primary care physicians face in diagnosing and treating depression, noting that up to one-third of antidepressant prescriptions involve non-indicated use; it also introduces FDA-approved treatments, esketamine nasal spray, and brexanolone IV injection.

Lower doses of oral minoxidil can promote hair growth without major heart risks.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

This study reports that topical minoxidil 5% foam may effectively promote hair growth in congenital alopecia and hypotrichosis linked to desmoplakin mutations, as demonstrated by significant hair growth in an 8-year-old boy.

This study found that low power red laser therapy, combined with antiretroviral drug efavirenz, significantly reduces HIV-1 infection in TZM-bl cells to undetectable levels.

In this study, cetirizine hydrochloride was formulated into niosomal and cubosomal gels, showing potential for off-label use in treating androgenic alopecia due to effective skin permeation and acceptable safety profiles; cubosomal gels exhibited superior permeation compared to niosomal gels.

This study found that self-supervised pretraining significantly improves accuracy in medical image classifiers for dermatology and chest X-ray tasks, outperforming supervised baselines and showing robustness to distribution shifts with limited labeled data.

This study found that keratin 19 may be a marker for skin stem cells, helping to characterize these cells in different conditions and potentially explaining variations in healing rates between children and adults.

This study found that a new 5% minoxidil foam formulation significantly increased hair counts and improved hair loss condition in men with androgenetic alopecia over 16 weeks compared to placebo.

This review discusses methotrexate's use in dermatology and its mechanisms, pharmacokinetics, dosing, side effects, interactions, and emphasizes the need for further research into optimizing therapy and predicting adverse events.

This review presents substantial evidence supporting testosterone use for hypoactive sexual desire disorder in postmenopausal women, but notes safety concerns with off-label prescribing due to lack of approved formulations.

This study found that injury affects the behavior of hair follicle dermal stem cells, steering them towards recruitment into the dermal papilla, a shift influenced by the hair cycle stage.

This study found that basal keratinocytes in engineered skin substitutes showed a proliferative phenotype and potential for long-term replication, which may enhance wound healing stability.

This review discusses the cutaneous side effects of targeted anticancer therapies, such as rashes and hair changes, but presents no new clinical results.

This source provides an overview of expert practices for using topical and low-dose oral minoxidil in treating hair loss, highlighting how dermatologists apply existing literature to ensure safe and effective treatment.

This study found that despite only topical minoxidil and oral finasteride being approved for androgenetic alopecia in Spain, dermatologists commonly prescribe various off-label treatments for both male and female patients.

This consensus statement outlines a treatment algorithm for alopecia areata, detailing systemic treatment indications and options, including EMA-approved medications baricitinib and ritlecitinib for severe cases, as well as other off-label treatments and adjuvant therapies like oral minoxidil.

Hair enzyme activity predicts minoxidil success in Brazilian women with hair loss.

This case report describes a patient with Birt-Hogg-Dube syndrome exhibiting multiple fibrofolliculomas, acrochordons, and renal oncocytoma.

This review examined the role, efficacy, and safety of Janus kinase inhibitors in treating alopecia areata, noting that baricitinib has received approval as the first on-label treatment due to positive outcomes in multiple trials.

This review explores the current treatments for different types of alopecia, emphasizing the need for well-designed clinical trials and highlighting that most therapies are used off-label, as only androgenetic alopecia has FDA-approved drugs.

Sea holly extract may help reduce hair loss.

IMG-007 helps regrow hair and reduce scalp inflammation in severe alopecia areata.

This study evaluated the safety and effectiveness of MNC-QQ cell therapy in five men with androgenic alopecia, reporting no adverse effects and improvements in hair growth, hair density, and quality of life over six months.

This study established a Krt24-CreERT2 mouse line targeting outer bulge hair follicle stem cells, finding these cells crucial for hair follicle development and repair, particularly following ionizing radiation exposure.